Neoadjuvant anlotinib/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): Phase 2 trial
Liulu Zhang(Southwest Medical University), Kun Wang(Union Hospital), Ciqiu Yang(Guangdong Academy of Medical Sciences), Hongfei Gao(Guangdong Academy of Medical Sciences), Bo Chen(Southern University of Science and Technology), Yan Ge(National University of Singapore), Lu Yang(Capital Medical University), Zhaowen Zhu(University of Iowa), Mei Yang(Tongji University), Teng Zhu(Guangdong Academy of Medical Sciences)
Cited by 9
Related Papers
Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells
|Molecular Cancer|2011|700
MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor
|Clinical Cancer Research|2009|435
Cytosolic escape of mitochondrial DNA triggers cGAS-STING-NLRP3 axis-dependent nucleus pulposus cell pyroptosis
|Experimental & Molecular Medicine|2022|321
MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1
|Oncogene|2011|248
Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis
|Clinical Rheumatology|2010|230